Plant ID: NPO14318
Plant Latin Name: Lespedeza davidii
Taxonomy Genus: Lespedeza
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
701534
Plant-of-the-World-Online:
n.a.
LCK; FYN; MAPK1; MAPK14; | |
CA2; CA7; CA12; | |
NR1H4; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 5 | TBXAS1 | Thromboxane-A synthase | P24557 | CHEMBL1835 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Protein Kinase | LCK | Tyrosine-protein kinase LCK | P06239 | CHEMBL258 |
Protein Kinase | FYN | Tyrosine-protein kinase FYN | P06241 | CHEMBL1841 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MAPK14 | MAP kinase p38 alpha | Q16539 | CHEMBL260 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 6.228E-08 | 6.643E-04 | CA12, CA2, CA7 |
MF | GO:0005488; binding | GO:0042610; CD8 receptor binding | 2.948E-07 | 1.605E-03 | FYN, LCK |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 8.842E-07 | 2.349E-03 | CA2, CA7 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.709E-07 | 2.349E-03 | CA12, CA2, CA7 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.797E-06 | 3.556E-03 | CA12, CA2, CA7 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.063E-06 | 6.320E-03 | CA2, CA7, FYN, LCK |
MF | GO:0005488; binding | GO:0042608; T cell receptor binding | 6.182E-06 | 7.478E-03 | FYN, LCK |
MF | GO:0005488; binding | GO:0042609; CD4 receptor binding | 6.182E-06 | 7.478E-03 | FYN, LCK |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.214E-07 | 1.273E-05 | LCK, MAPK1, FYN, MAPK14 |
09150 Organismal Systems | 09151 Immune system | hsa04611 | Platelet activation | 4.207E-07 | 1.613E-05 | TBXAS1, MAPK1, FYN, MAPK14 |
09150 Organismal Systems | 09158 Development | hsa04380 | Osteoclast differentiation | 5.772E-07 | 1.659E-05 | LCK, MAPK1, FYN, MAPK14 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 8.381E-08 | 9.638E-06 | CA12, CA2, CA7 |
09150 Organismal Systems | 09151 Immune system | hsa04664 | Fc epsilon RI signaling pathway | 6.083E-06 | 1.399E-04 | MAPK1, FYN, MAPK14 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 3.356E-05 | 6.432E-04 | MAPK1, FYN, MAPK14 |
09150 Organismal Systems | 09151 Immune system | hsa04650 | Natural killer cell mediated cytotoxicity | 4.770E-05 | 7.837E-04 | LCK, MAPK1, FYN |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 4.944E-04 | 5.366E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09163 Neurodegenerative diseases | hsa05020 | Prion diseases | 1.620E-04 | 2.329E-03 | MAPK1, FYN |
09150 Organismal Systems | 09151 Immune system | hsa04621 | NOD-like receptor signaling pathway | 4.317E-04 | 5.366E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 6.883E-04 | 5.366E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 7.075E-04 | 5.366E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05131 | Shigellosis | 5.613E-04 | 5.366E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 6.694E-04 | 5.366E-03 | CA2, NR1H4 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 7.269E-04 | 5.366E-03 | MAPK1, FYN |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.348E-03 | 7.383E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04912 | GnRH signaling pathway | 1.097E-03 | 7.005E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.270E-03 | 7.383E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05133 | Pertussis | 7.466E-04 | 5.366E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09156 Nervous system | hsa04723 | Retrograde endocannabinoid signaling | 1.348E-03 | 7.383E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 1.625E-03 | 7.475E-03 | MAPK1, FYN |
09160 Human Diseases | 09167 Infectious diseases | hsa05132 | Salmonella infection | 9.802E-04 | 6.630E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 1.483E-03 | 7.417E-03 | MAPK1, MAPK14 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.596E-03 | 7.475E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 1.429E-03 | 7.417E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 1.833E-03 | 8.073E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 1.895E-03 | 8.073E-03 | MAPK1, MAPK14 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 2.321E-03 | 8.897E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09158 Development | hsa04360 | Axon guidance | 2.119E-03 | 8.705E-03 | MAPK1, FYN |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04068 | FoxO signaling pathway | 2.321E-03 | 8.897E-03 | MAPK1, MAPK14 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04072 | Phospholipase D signaling pathway | 2.713E-03 | 9.574E-03 | MAPK1, FYN |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 2.640E-03 | 9.574E-03 | MAPK1, MAPK14 |
09150 Organismal Systems | 09153 Circulatory system | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.863E-03 | 9.685E-03 | MAPK1, MAPK14 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.747E-03 | 9.574E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MAPK14; |
H00-H59: Diseases of the eye and adnexa | Diabetic retinopathy | H36, E10.3, E11.3, E13.3 | MAPK14; |
J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | MAPK14; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | TBXAS1; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | TBXAS1; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | TBXAS1; |
NA: NA | Rheumatold arthritis | NA | MAPK14; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | MAPK14; |
C00-D49: Neoplasms | Cancer | C00-C96 | MAPK1; MAPK14; |
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | TBXAS1; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | TBXAS1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | MAPK14; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | MAPK14; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | MAPK14; TBXAS1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MAPK14; |
NA: NA | Inflammatory diseases | NA | MAPK14; |
N00-N99: Diseases of the genitourinary system | Nephritis | N00-N19, N25-N29 | TBXAS1; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | TBXAS1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | LCK; |
I00-I99: Diseases of the circulatory system | Coronary artery disease | I20-I25 | MAPK14; |
I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | MAPK14; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
NA: NA | Acute respiratory distress syndrome | NA | MAPK14; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |